Pyoderma gangrenosum is an immune-mediated inflammatory condition characterized by ulcerative skin lesions. The condition affects 1-2% of patients with inflammatory bowel disease (IBD).
Current treatments for pyoderma gangrenosum include wound care, antibiotics, corticosteroids, and immunomodulators. However, many patients have disease which is refractory to these treatments.
Dr Miguel Regueiro and colleagues at the Universities of Pittsburgh and Florida assessed the response of medically refractory pyoderma gangrenosum to infliximab.
Dr Regueiro’s team conducted a retrospective study of IBD patients with pyoderma gangrenosum who had been treated with infliximab.
13 of 13 patients with moderate to severe pyoderma gangrenosum and IBD treated with infliximab demonstrated complete healing of the skin lesions.
3 of the 13 patients had a complete response to infliximab therapy and did not require additional treatment.
The remaining10 patients responded well to infliximab and have maintained pyoderma gangrenosum healing with infusions every 4–12 weeks.
|13 out of 13 patients demonstrated complete healing of skin lesions after infliximab.
|The American Journal of Gastroenterology|
Patients who were receiving corticosteroids were able to discontinue them completely after infliximab treatment.
Infliximab therapy was well tolerated and safe.
Dr Riguero concludes. “Infliximab is a safe and effective treatment for IBD-associated pyoderma gangrenosum”